---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-039263"
form_type: "8-K"
ticker: null
cik: "0001012477"
company_name: "AVADEL PHARMACEUTICALS PLC"
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T08:49:24.786970+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avadel Pharmaceuticals announces $117M public offering of ordinary shares and preferred shares

## Summary
- Offering of up to 12,205,883 ordinary shares (via ADSs) and 4,705,882 Series B non-voting convertible preferred shares.
- Net proceeds expected ~$117M; ~$134.6M if underwriters exercise 30-day option for additional 2,205,882 ADSs.
- Preferred shares convertible into ordinary shares, subject to 9.99% beneficial ownership cap; not listed on Nasdaq.
- Closing expected on or about April 3, 2023, subject to customary conditions.
- Underwriting agreement with Jefferies LLC as representative of underwriters.

## SEC filing metadata
- accession: 0001104659-23-039263
- form_type: 8-K
- cik: 0001012477
- company_name: AVADEL PHARMACEUTICALS PLC
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1012477/000110465923039263/0001104659-23-039263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1012477/000110465923039263/tm2310752d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-039263
- JSON: https://secwatch.observer/filing/0001104659-23-039263.json
- Plain text: https://secwatch.observer/filing/0001104659-23-039263.txt

## Key facts
- Governance Changes
  AVADEL PHARMACEUTICALS PLC: Board approved Certificate of Designation for Series B Non-Voting Convertible Preferred Shares, setting forth powers, preferences, rights, qualifications, limitations and restrictions (effective 2023-03-28).
  - Change: fiscal year change
  - Effective: 2023-03-28
  source text: Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The Board of Directors approved the Certificate of Designation on March 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1012477/000110465923039263/0001104659-23-039263-index.htm
- Material Agreements
  AVADEL PHARMACEUTICALS PLC entered into Underwriting Agreement with Jefferies LLC valued at approximately $117.0 million (effective 2023-03-29).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC
  - Value: approximately $117.0 million
  - Effective: 2023-03-29
  source text: On March 29, 2023, Avadel Pharmaceuticals plc (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, as representative of the several underwriters (the “Underwriters”), relating to the registered public offering (the “Offering”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1012477/000110465923039263/0001104659-23-039263-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.